Research to Practice (RTP) 15th Annual Winter Lung Cancer Conference
In-Person Event
Mar 02 - 04, 2018
Aventura, Florida, USA
OVERVIEW
Research to Practice (RTP) 15th Annual Winter Lung Cancer Conference is organized by Research to Practice (RTP) and would be held during Mar 2 - 4, 2018 at Turnberry Isle Miami, Aventura, Florida, United States Of America. This cme conference has been approved with a maximum of 10.25 AMA PRA Category 1 Credits.
Target Audience
This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.
Objectives
• Design evidence-based strategies for the diagnosis and management of Stage I to Stage III non-small cell lung cancer (NSCLC), considering the potential contributions of systemic and/or local therapeutic modalities.
• Evaluate existing guideline recommendations regarding the indications and optimal testing platform for mutational analysis in patients with metastatic NSCLC, and utilize this information to implement a comprehensive approach to genomic assessment.
• Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, assess which testing platform(s) should be utilized, and appropriately employ the results of these assessments to individualize first- and later-line therapy for patients with NSCLC based on their potential response (or lack thereof) to a specific treatment.
• Review published research data documenting the safety and efficacy of anti-PD-1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
Additional details will be posted as soon as they are available
Target Audience
This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.
Objectives
• Design evidence-based strategies for the diagnosis and management of Stage I to Stage III non-small cell lung cancer (NSCLC), considering the potential contributions of systemic and/or local therapeutic modalities.
• Evaluate existing guideline recommendations regarding the indications and optimal testing platform for mutational analysis in patients with metastatic NSCLC, and utilize this information to implement a comprehensive approach to genomic assessment.
• Recognize available and emerging research information validating the utility of diagnostic assays designed to measure EGFR, ALK, ROS1, BRAF and PD-L1 status, assess which testing platform(s) should be utilized, and appropriately employ the results of these assessments to individualize first- and later-line therapy for patients with NSCLC based on their potential response (or lack thereof) to a specific treatment.
• Review published research data documenting the safety and efficacy of anti-PD-1 antibodies used as monotherapy or in combination with chemotherapy for patients with newly diagnosed metastatic NSCLC.
Additional details will be posted as soon as they are available
KEY DATES
02 Mar, 2018
Event Start Date
04 Mar, 2018
Event End Date
SPECIALITIES
Medical EducationPractice ManagementSUGGESTED HOTELS
CONFERENCE VENUE
Turnberry Isle MiamiRELATED CONFERENCES & LIVE WEBINARS
Quick Links